GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Psychemedics Corp (NAS:PMD) » Definitions » Net Cash per Share

Psychemedics (Psychemedics) Net Cash per Share : $-0.64 (As of Dec. 2023)


View and export this data going back to 1987. Start your Free Trial

What is Psychemedics Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Psychemedics's Net Cash per Share for the quarter that ended in Dec. 2023 was $-0.64.

The historical rank and industry rank for Psychemedics's Net Cash per Share or its related term are showing as below:

During the past 13 years, the highest Price-to-Net-Cash Ratio of Psychemedics was 411.20. The lowest was 49.59. And the median was 230.40.

PMD's Price-to-Net-Cash is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 7.31
* Ranked among companies with meaningful Price-to-Net-Cash only.

Psychemedics Net Cash per Share Historical Data

The historical data trend for Psychemedics's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psychemedics Net Cash per Share Chart

Psychemedics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.62 -1.56 -1.31 -0.57 -0.64

Psychemedics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.57 -0.59 -0.84 -0.91 -0.64

Competitive Comparison of Psychemedics's Net Cash per Share

For the Diagnostics & Research subindustry, Psychemedics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Psychemedics's Price-to-Net-Cash Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Psychemedics's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Psychemedics's Price-to-Net-Cash falls into.



Psychemedics Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Psychemedics's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(1.964-5.654-0)/5.806
=-0.64

Psychemedics's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

Net Cash per Share (Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(1.964-5.654-0)/5.806
=-0.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Psychemedics  (NAS:PMD) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Psychemedics Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Psychemedics's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Psychemedics (Psychemedics) Business Description

Traded in Other Exchanges
N/A
Address
289 Great Road, Suite 200, Acton, MA, USA, 01720
Psychemedics Corp is engaged in providing testing services for the detection of drugs of abuse through the analysis of hair samples. The company operates through a single segment of drug testing services which include training for the collection of samples and storage of positive samples for its customers for an agreed-upon fee per unit testing of samples. The testing methods of the company utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. Geographically it generates the majority of its revenue from the United States.
Executives
Shannon Shoemaker officer: Chief Revenue Officer 289 GREAT ROAD, SUITE 200, ACTON MA 01720
Charles M Doucot officer: Executive Vice President 289 GREAT ROAD, SUITE 200, ACTON MA 01720
Andrew Reynolds director C/O FLEETMATICS, 1100 WINTER STREET, 4TH FL, WALTHAM MA 02451
Brian Hullinger director, officer: President & CEO 289 GREAT ROAD, SUITE 200, ACTON MA 01720
Robyn C Davis director ONE WALLINGFORD ROAD, MARBLEHEAD MA 01945
Michael Weisenhoff other: Assistant Controller 289 GREAT ROAD, SUITE 200, ACTON MA 01720
Michael I Schaffer officer: VP of Laboratory Operations C/O PAYCHEMEDICS CORP, 1280 MASSACHUSETTS AVE STE 200, CAMBRIDGE MA 02138
William B. Norris other: Assistant Controller 289 GREAT ROAD, SUITE 200, ACTON MA 01720
Darius G Nevin other: See Footnote 1 C/O WCI COMMUNITIES, INC., 24301 WALDEN CENTER DRIVE, BONITA SPRINGS FL 34134
Peter H Kamin 10 percent owner 2720 DONALD ROSS ROAD, #311, PALM BEACH GARDENS FL 33410
Andrew Limbek officer: Vice President & Controller 289 GREAT ROAD, SUITE 200, ACTON MA 01720
Fred J Weinert director 330 E MAIN ST, BARRINGTON IL 60620
Kubacki Raymond C Jr director, officer: Chairman, CEO & President 125 NAGOG PARK, ACTON MA 01720
A Clinton Allen director, officer: Chairman 1280 MASSACHUSETTS AVE STE 200, CAMBRIDGE MA 02138
Neil Lerner officer: VP - Finance C/O PSYCHEMEDICS CORPORATION, 125 NAGOG PARK, ACTON MA 01720